| B Lymphoblastic Leukemia/Lymphoma studied in …STUDIED_INderived200 of 373show all (up to 200) |
|---|
| → studied in | NCT03739814Phase 2 · recruiting Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05621291NA · recruiting A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06738368Phase 2 · suspended Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07572136Phase 1 · recruiting Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06124157Phase 2 · recruiting A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02458014Phase 2 · completed Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06144606Phase 2 · recruiting Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06317662Phase 2 · recruiting Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07570173Phase 2/Phase 3 · recruiting A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07838714Phase 1 · recruiting Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02003222Phase 3 · active not recruiting Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07830238early Phase 1 · not yet recruiting SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06395103Phase 1/Phase 2 · recruiting Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07223021Phase 3 · recruiting A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04094311Phase 3 · recruiting Study of Out of Specification for Tisagenlecleucel · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01219816Phase 2 · completed Multi-centric Study · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544592Phase 1/Phase 2 · recruiting UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07328503Phase 2 · recruiting CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07674823Phase 1 · not yet recruiting Study Of KITE-753 in R/R B-Cell ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03666000Phase 1 · recruiting Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03150693Phase 3 · recruiting Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05470777Phase 2 · active not recruiting CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05707273Phase 1 · active not recruiting CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04546399Phase 2 · recruiting A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04530565Phase 3 · active not recruiting Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00792948Phase 2 · active not recruiting Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03959085Phase 3 · recruiting Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05702645recruiting A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia Associated with Down Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05262673Phase 1 · terminated NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05602194Phase 3 · active not recruiting Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02879695Phase 1 · active not recruiting Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03007147Phase 3 · active not recruiting Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03876769Phase 2 · active not recruiting Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05082519Phase 2 · recruiting Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06137118Phase 1/Phase 2 · recruiting AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06710418NA · recruiting Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07556757Phase 1 · terminated A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07153796Phase 1/Phase 2 · active not recruiting A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07770698Phase 1/Phase 2 · not yet recruiting A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06703216Phase 1/Phase 2 · withdrawn Pre-emptive Anakinra for Cytokine Event Reduction · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07224100Phase 2 · recruiting Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07313852Phase 1/Phase 2 · not yet recruiting A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07758673Phase 1 · not yet recruiting Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03441061Phase 2 · active not recruiting Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06287229Phase 1/Phase 2 · recruiting Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07754682Phase 3 · not yet recruiting Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03504644Phase 1/Phase 2 · active not recruiting Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533579Phase 1/Phase 2 · recruiting Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02146924Phase 1 · active not recruiting Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02143414Phase 2 · active not recruiting Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07117136recruiting Blinatumomab Consolidation in Real World · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02727803Phase 2 · recruiting Personalized NK Cell Therapy in CBT · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02981628Phase 2 · active not recruiting Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03488225Phase 2 · terminated Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914625Phase 3 · active not recruiting A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05442515Phase 1/Phase 2 · recruiting CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06785818recruiting Long-term Follow up Local Registry Study of Kymriah in South Korea · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101853Phase 3 · active not recruiting Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05397496Phase 1 · active not recruiting Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06764238Phase 2/Phase 3 · recruiting Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07205315early Phase 1 · recruiting A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07246707Phase 1 · recruiting KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07532525Phase 1 · recruiting Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01371630Phase 1/Phase 2 · recruiting Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07133997Phase 1 · recruiting Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07109219Phase 1/Phase 2 · recruiting Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05303792Phase 2 · active not recruiting Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03241940Phase 1 · active not recruiting Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07575971Phase 1/Phase 2 · recruiting Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06579469recruiting Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07040982Phase 1 · recruiting Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07575919Phase 1/Phase 2 · recruiting Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02997761Phase 2 · completed Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07636564Phase 2 · not yet recruiting Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01860937Phase 1 · active not recruiting T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07614022Phase 1 · not yet recruiting A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07623655not yet recruiting CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02883049Phase 3 · completed Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05418088Phase 1 · recruiting Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01190930Phase 3 · completed Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | Adult B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05157971Phase 1 · active not recruiting Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05480449Phase 1/Phase 2 · recruiting Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02877303Phase 2 · recruiting Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04318678Phase 1 · recruiting CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06777979Phase 1 · recruiting CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06879340Phase 1 · recruiting Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03808610Phase 1/Phase 2 · terminated Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07454226NA · recruiting ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05453500Phase 2 · active not recruiting Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03984968Phase 1/Phase 2 · active not recruiting CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04872790Phase 1 · active not recruiting Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07564453Phase 2 · recruiting Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07048535recruiting CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02315612Phase 1 · completed Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020678Phase 1 · active not recruiting NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07539610Phase 1 · not yet recruiting Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01424982Phase 2 · active not recruiting Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03856216Phase 2 · terminated Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208735Phase 1 · recruiting CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07509385not yet recruiting The Role of Serum Cytokines IL_17 A and IL_10 in Disease Activity of Acute B Lymphoblastic Leukemia in South Egypt · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04088890Phase 1 · completed Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06880913Phase 1/Phase 2 · recruiting Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502118Phase 2/Phase 3 · recruiting NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05674175Phase 1/Phase 2 · recruiting Co-administration of CART22-65s and huCART19 for B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06918431Phase 2 · recruiting Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07476729Phase 3 · not yet recruiting International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06343090NA · recruiting Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06326008Phase 1 · recruiting Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06481228NA · recruiting Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06481241NA · recruiting Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06799221available Expanded Access Program for OOS Obe-cel · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07441291Phase 3 · recruiting CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06389305NA · recruiting CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07422337recruiting A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Lymphoblastic Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07429461early Phase 1 · recruiting Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06863259Phase 1 · recruiting Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04512716early Phase 1 · recruiting Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05350787Phase 1 · completed Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07412405NA · not yet recruiting This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06287528Phase 1 · recruiting A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580301Phase 1/Phase 2 · recruiting Study of YK012 in B-cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05366218Phase 1/Phase 2 · recruiting Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05460533Phase 2 · active not recruiting A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05016947Phase 1 · active not recruiting Venetoclax Plus Inotuzumab for B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04681105Phase 1 · completed Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07335094early Phase 1 · not yet recruiting A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Lymphoblastic Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06514768early Phase 1 · recruiting JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03698552Phase 1/Phase 2 · terminated ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07277504early Phase 1 · not yet recruiting Autologous Bedside CD19 CAR T-cell Therapy for B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02328014Phase 1/Phase 2 · completed Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06080191Phase 1 · recruiting Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07256353early Phase 1 · not yet recruiting Allogeneic UCB-derived CAR-T for B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06559189Phase 1 · recruiting CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07244406Phase 2 · recruiting Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06507514Phase 1 · recruiting Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01139970Phase 1 · completed Veliparib and Temozolomide in Treating Patients With Acute Leukemia · condition mapped ONTOLOGY_EXACT · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07239323Phase 1 · recruiting In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03233854Phase 1 · active not recruiting CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02050347Phase 1 · active not recruiting Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03160079Phase 1/Phase 2 · completed Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04148430Phase 2 · active not recruiting A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04260022Phase 1 · recruiting Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03595917Phase 1 · recruiting ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04035434Phase 1/Phase 2 · terminated A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03480438Phase 2 · completed Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04501614Phase 1/Phase 2 · terminated A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07039877Phase 2 · recruiting Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07199855Phase 2 · active not recruiting Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04150497Phase 1/Phase 2 · recruiting Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06027957Phase 1 · completed CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06882057Phase 2/Phase 3 · recruiting Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07113496Phase 1 · not yet recruiting RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05667506Phase 1/Phase 2 · recruiting A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05032183Phase 1/Phase 2 · terminated Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06009107Phase 1/Phase 2 · withdrawn A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06213636Phase 1/Phase 2 · recruiting Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06220097Phase 2 · active not recruiting Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06689917NA · recruiting JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07043218Phase 1 · not yet recruiting A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06785324NA · recruiting Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06940960NA · recruiting JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02420717Phase 2 · terminated Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03448393Phase 1 · completed CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02975687Phase 1 · completed CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03937544Phase 2/Phase 3 · recruiting Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03472573Phase 1 · completed Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06890065NA · recruiting JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04556084Phase 2 · terminated Blinatumomab Bridging Therapy for BALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03509961Phase 2 · recruiting The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06462365Phase 1 · recruiting Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06911710Phase 1/Phase 2 · recruiting The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06902025NA · not yet recruiting JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06581081NA · recruiting Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02484430Phase 2 · completed Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02828358Phase 2 · completed Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03751709Phase 1 · completed Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06793241early Phase 1 · recruiting Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722848Phase 3 · active not recruiting Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06307600early Phase 1 · recruiting The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Lymphoblastic Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06777264Phase 2 · not yet recruiting Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1 · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05281809Phase 2 · recruiting Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06179524Phase 2 · recruiting CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06735495Phase 1/Phase 2 · recruiting CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Lymphoblastic Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06696833early Phase 1 · recruiting Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393985Phase 2 · recruiting Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06034275Phase 1 · recruiting Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06678282NA · recruiting JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06608732Phase 2 · recruiting Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06658938NA · not yet recruiting Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04475731Phase 2 · active not recruiting Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Childhood B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04788472Phase 2 · completed Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06607419Phase 2/Phase 3 · recruiting Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05557110Phase 2 · completed Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06450067recruiting Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05333302Phase 1 · unknown Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06559644early Phase 1 · not yet recruiting Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06554626Phase 2 · recruiting Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04545333terminated The clonoSEQ® Watch Registry · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | Adult B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06503094Phase 1/Phase 2 · unknown CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors · condition mapped ALIAS · 373 trials mapped (173 active) | — | — | B Lymphoblastic Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05936229Phase 1/Phase 2 · withdrawn Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy · condition mapped CURATED_BROADER · 373 trials mapped (173 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |